Immuneering (Nasdaq:IMRX) - Aandelenkoers, Nieuws & Analyse

IMRX Overzicht aandelen

Immuneering Corporation, een oncologisch bedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van geneesmiddelen voor een brede groep kankerpatiënten.

Over het bedrijf

IMRX fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 11.3% per jaar dalen.

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

+ 2 meer risico's

Immuneering Corporation Concurrenten

SELLAS Life Sciences Group

NasdaqCM:SLS

US$76.6m

I-Mab

NasdaqGM:IMAB

US$87.1m

Entera Bio

NasdaqCM:ENTX

US$65.4m

vTv Therapeutics

NasdaqCM:VTVT

US$42.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Immuneering
Historische aandelenkoersen
Huidige aandelenkoers	US$1.86
52 Week Hoogtepunt	US$8.89
52 Week Laag	US$1.00
Bèta	-0.45
11 maand verandering	-24.70%
3 maanden verandering	50.00%
1 Jaar Verandering	-69.00%
33 jaar verandering	-94.00%
5 jaar verandering	n/a
Verandering sinds IPO	-89.43%

Recent nieuws en updates

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Aug 30

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

May 13

Recent updates

Rendement voor aandeelhouders

	IMRX	US Biotechs	US Markt
7D	-13.1%	-1.4%	-1.9%
1Y	-69.0%	20.2%	30.4%

Rendement versus industrie: IMRX presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 20.2 % opleverde.

Rendement versus markt: IMRX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.4 % opleverde.

Prijsvolatiliteit

Is IMRX's price volatile compared to industry and market?
IMRX volatility
IMRX Average Weekly Movement	22.8%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van IMRX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 23% ) van IMRX is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	66	Ben Zeskind	immuneering.com

Immuneering Corporation, een oncologiebedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van geneesmiddelen voor een brede groep kankerpatiënten. Haar belangrijkste productkandidaten zijn IMM-1-104, een dubbele MEK-remmer die momenteel in Fase 1/2a klinische studie wordt onderzocht voor de behandeling van patiënten met kanker, waaronder alvleesklierkanker, melanoom, colorectale kanker en niet-kleincellige longkanker veroorzaakt door mutaties van RAS en/of RAF; en IMM-6-415 is in Investigational New Drug aanvraag voor de behandeling van solide tumoren. Immuneering Corporation werd opgericht in 2008 en is gevestigd in Cambridge, Massachusetts.

Immuneering Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Immuneering zich tot de beurswaarde?
IMRX fundamentele statistieken
Marktkapitalisatie	US$55.45m
Inkomsten(TTM)	-US$56.07m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.0x

Koers/Winstverhouding

Is IMRX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IMRX resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$56.07m
Inkomsten	-US$56.07m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.89
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde IMRX op de lange termijn?

Bekijk historische prestaties en vergelijking

IMRX Overzicht aandelen

Beloningen

Risicoanalyse

Immuneering Corporation Concurrenten

NasdaqCM:SLS

US$76.6m

NasdaqGM:IMAB

US$87.1m

NasdaqCM:ENTX

US$65.4m

NasdaqCM:VTVT

US$42.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Recent updates

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations

Independent Chair recently bought US$123k worth of stock

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Price target decreased by 12% to US$16.86

Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Share price stability

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Revenue and earnings growth

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Price target decreased by 12% to US$18.71

Consensus revenue estimates decrease by 80%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$21.33

Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering wins FDA nod to study lead asset in solid tumors

Immuneering Corporation Announces Committee Changes

Consensus forecasts updated

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immuneering Corporation Announces Management Changes

Immuneering initiated a Buy by Chardan, PT set to $18

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

Immuneering Corporation, Annual General Meeting, Jun 21, 2022

Consensus revenue estimates fall by 75%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model

Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million.

Third quarter 2021 earnings released: US$0.47 loss per share

Director recently bought US$116k worth of stock

Director recently bought US$131k worth of stock

Less than half of directors are independent